SHORT COMMUNICATION
955
A Monocentric Retrospective Cohort of Patients with Severe Atopic Dermatitis Treated with
Cyclosporine A in Daily Practice
Justine DAGUZÉ 1 , Hélène AUBERT 1 , Claire BERNIER 1 , Aurélie GAULTIER 2 , Jean-Michel NGUYEN 2 , Jean-François STALDER 1
and Sébastien BARBAROT 1 *
Departments of 1 Dermatology,and 2 Epidemiology and Biostatistics, CHU Hôtel-Dieu, 1 place A Ricordeau, FR-44093 Nantes cedex, France.
*E-mail: [email protected]
Accepted Apr 27, 2017; Epub ahead of print Apr 27, 2017
Atopic dermatitis (AD) is the most common chronic
inflammatory skin disease (1, 2). Systemic immunosup-
pressive treatments may be required for a minority of
patients with recalcitrant severe disease. The strongest
evidence for efficacy in patients with severe AD was
obtained for cyclosporine A (CsA) (3), which is the only
approved immunosuppressive treatment for this indica-
tion in Europe (4, 5). As novel biologic treatments are
currently undergoing development for use in AD (6), it
is of utmost importance to evaluate the effectiveness of
CsA in a real-life setting in order to obtain a clear picture
of the unmet needs in patients with severe AD.
Drug survival is the time patients remain on a specific
drug (7). Performing drug survival studies with chronic
diseases in a real-life setting is a way of assessing long-
term drug effectiveness and safety. However, only one
study has reported drug survival data for CsA in a long-
term daily practice cohort of adult patients with AD (8). As
the outcomes of drug survival studies may be influenced
by specific behaviours of physicians and patients, it is
important to replicate this study in other settings in order
to establish the more general relevance of the findings.
The aim of the current study was to perform a detailed
analysis of CsA modaliti